CatalystAlertBeta

Briefing Calendar News IPOs Catalyst Radar Research Companies Compare Analytics Watchlist Learn

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Loading market movers...

CatalystAlert is a biotech catalyst intelligence platform tracking FDA decisions, PDUFA dates, and clinical-trial readouts for 1,600+ biotech stocks. Every catalyst date carries a confidence rating — confirmed against an official regulatory source, estimated, or AI-detected — alongside AI entry-timing and a public, scored prediction track record.

Quick Links

This Week's Catalysts
Full Calendar
Catalyst Types
Search Companies
Short Interest
Smart Money
Biotech Glossary
Best Catalyst Tools
What's New

Compare

vs BioPharmCatalyst
vs BioMarkets.io
vs Biocat
vs BioCatalyst
vs ClinicalInvestor

Legal

About
CeliA (AI assistant)
ML Track Record
Privacy
Terms
Cookies

Data Sources

ClinicalTrials.gov
SEC EDGAR
FDA

Follow Us

Legal & disclaimer

Not Financial Advice: CatalystAlert is an informational platform only. We are NOT a registered investment advisor, broker, or dealer. The information provided on this website does not constitute investment advice, financial advice, trading advice, or any other sort of advice, and you should not treat any of the website's content as such.

No Guarantees: All signals, probability scores, and analyses are based on historical data and machine-learning models. Past performance does not guarantee future results, and biotech is a volatile sector where outcomes are uncertain.

Data Accuracy: While we strive for accuracy, data may be incomplete, delayed, or contain errors. We aggregate data from third-party sources (FDA, SEC, ClinicalTrials.gov) and are not responsible for their accuracy. Always verify information with official sources before making any decisions.

Your Responsibility: You are solely responsible for your investment decisions. Consult a qualified financial advisor before investing. CatalystAlert and its operators accept no liability for any losses incurred from using this platform.

© 2026 CatalystAlert. All rights reserved.

Data may be delayed or incomplete. Use at your own risk.

Home Calendar Watchlist News Learn Account

RXRX Phase 2 readout — July 15, 2026: -1% | CatalystAlert

July 15, 2026 · Phase 2 readout

RXRX Phase 2 readout: a neutral outcome, -0.9%

-0.9%Recursion Pharmaceuticals, Inc. (RXRX) →

On July 15, 2026, REC-4881 — Recursion Pharmaceuticals, Inc. (AXIN1 Gene Mutation) reached its Phase 2 readout. The result was a neutral outcome, and the stock moved -0.9% in the window around the event. It had already run +8.2% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.

The move

$3.34

1d before

$3.31

Event day

$3.02

1d after

$2.89

5d after

Our prediction vs. the result

CatalystAlert called this one neutral (+3.0% expected); the stock actually moved -0.9%. Model confidence at the time: 68%.

See the full scored track record

Pre-catalyst setup

+8.2%

30-day run-up

5594%

30-day volatility

1.1×

volume spike

RXRX catalyst calendar More Phase 2 readouts Prediction track record Full catalyst calendar